Item 1

Call to order

Item 2

Consideration of minutes from April 23, 2021, meeting (vote required)

Item 3

Amendments proposed to Texas Administrative Code concerning the Drug Utilization Review Board and conflict of interest policy

Item 4

Public comment on the drug classes to be reviewed for the Medicaid Preferred Drug List (PDL):
a. Alzheimers agents
b. Antihistamines, minimally sedating
c. Antihypertensives, sympatholytic
d. Calcium channel blockers
e. Cephalosporins and related antibiotics
f. Cytokine and cell adhesion module antagonists and related agents
g. Fluoroquinolones, oral
h. Glucocorticoids, oral
i. Immunosuppressives, oral
j. Iron, oral
k. Leukotriene modifiers
l. Nonsteroidal anti-inflammatory drugs (NSAIDs)
m. Ophthalmic antibiotics
n. Ophthalmic antibiotic-steroid combinations
o. Ophthalmics for allergic conjunctivitis
p. Ophthalmics, anti-inflammatories
q. Ophthalmic, anti-inflammatories/immunomodulators
r. Ophthalmics, glaucoma agents
s. Otic antibiotics
t. Otic anti-infectives and anesthetics
u. Penicillins
v. Platelet aggregation inhibitors
w. Progestational agents
x. Rosacea agents, topical
y. Skeletal muscle relaxants
z. Steroids, topical
aa. Ulcerative colitis agents

Item 5

Public comment on single new drugs to be reviewed for the Medicaid PDL:
a. Hetlioz liquid (oral) / Sedative-hypnotics
b. Ponvory starter pack (oral) / Multiple sclerosis agents
c. Ponvory tablet (oral) / Multiple sclerosis agents
d. Qelbree (oral) / Stimulants and related agents
e. Tepmetko tablet (oral) / Oncology, oral - lung
f. Trilociclo kit (topical) / Antifungals, topical
g. Ukoniq (oral) / Oncology, oral - hematologic
h. Vesicare LS (oral) / Bladder relaxant preparations

Item 6

Therapeutic and clinical drug reviews and updates: Magellan Medicaid Administration

Item 7

Executive work session
Pursuant to Texas Government Code Section 531.071, and in accordance with Texas Administrative Code Title
1, Part 15, Subchapter F, Section 354.1941(c)(2), the DURB may meet in executive session on one or more
items listed under new business as permitted by the Texas Open Meetings Act.

Item 8

Announcements of drugs recommended for the Medicaid PDL: Magellan Medicaid Administration (vote
required)

Item 9

Retrospective drug utilization review (DUR): Conduent, LLC
a. Report on recent retrospective DUR interventions:
i. Benzodiazepines anxiolytics and/or controlled sedative-hypnotics
ii. Major depressive disorder (MDD) management
b. Report on recent retrospective DUR intervention outcomes:
i. Asthma
ii. Pharmacotherapy of post-traumatic stress disorder
iii. Gabapentinoid drug use evaluation
iv. Overutilization of antibiotics
c. Retrospective DUR proposals: (vote required)
i. Bipolar disorder
ii. Hypertension

Item 10

Prospective prior authorization proposals (clinical edits): KEPRO, LLC (vote required)
a. Attention-Deficit / Attention Deficit Hyperactivity Disorder
i. Add Qelbree
b. Multiple sclerosis agents
i. New criteria for Ponvory (safety checks)
c. Phosphate Binders
i. Criteria revisions
d. Sedative/Hypnotics
i. Criteria revision for Hetlioz

Item 11

Retrospective drug use criteria for outpatient use in Vendor Drug Program:
The University of Texas at Austin College of Pharmacy (vote required)
a. Acetylcholinesterase inhibitors
b. Cyclooxygenase-2 inhibitors
c. Histamine H2-receptor antagonists
d. Ketorolac (oral)
e. Leukotriene receptor antagonists
f. Mecasermin
g. Memantine

Items 12 & 13

11. Next meeting date: October 22, 2021
12. Adjourn